trimethoprim has been researched along with Disease Models, Animal in 54 studies
Trimethoprim: A pyrimidine inhibitor of dihydrofolate reductase, it is an antibacterial related to PYRIMETHAMINE. It is potentiated by SULFONAMIDES and the TRIMETHOPRIM, SULFAMETHOXAZOLE DRUG COMBINATION is the form most often used. It is sometimes used alone as an antimalarial. TRIMETHOPRIM RESISTANCE has been reported.
trimethoprim : An aminopyrimidine antibiotic whose structure consists of pyrimidine 2,4-diamine and 1,2,3-trimethoxybenzene moieties linked by a methylene bridge.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The prophylactic effect of in-feed medication of conventional pigs with sulphadimethoxine (SDM), sulphamethoxazole (SMX), and trimethoprim (TMP) was tested by using an Actinobacillus pleuropneumoniae infection model." | 7.70 | Prevention of pleuropneumonia in pigs by in-feed medication with sulphadimethoxine and sulphamethoxazole in combination with trimethoprim. ( Kuiper, HA; Mengelers, MJ; Pijpers, A; van Miert, AS; Verheijden, JH, 2000) |
| "Trimethoprim-sulfadiazine and gentamicin sulfate decreased early mortality in an established model of fibrinous peritonitis in the rat." | 7.67 | Efficacies of trimethoprim-sulfadiazine and gentamicin sulfate in the treatment of fibrinous peritonitis in rats. ( Benson, CE; Emms, SG, 1987) |
| "Co-trimazine, a new combination of trimethoprim and sulphadiazine intended for treatment of urinary tract infections, was tested and compared to co-trimoxazole in an experimental model of acute, obstructive pyelonephritis in the rat." | 7.66 | Efficacy of two trimethoprim-sulphonamide combinations in experimental pyelonephritis in the rat. ( Ritzerfeld, W, 1979) |
| " Adult wild-type (WT) and Cxcr2-/- mice were fed a diet supplemented with sulfamethoxazole/trimethoprim (SMZ/TMP) during pregnancy and lactation, and their pups were injected intraperitoneally with rhesus rotavirus (RRV) within 24 hours of life to induce experimental biliary atresia." | 3.85 | Cxcr2 signaling and the microbiome suppress inflammation, bile duct injury, and the phenotype of experimental biliary atresia. ( Bezerra, JA; Fei, L; Jee, J; Mourya, R; Shivakumar, P; Wagner, M, 2017) |
| " JI, JC, and sham piglets commenced parenteral nutrition on day 0 and received ampicillin and trimethoprim-sulfadoxine on days 0-4 for prevention of line sepsis." | 3.85 | In a Neonatal Piglet Model of Intestinal Failure, Administration of Antibiotics and Lack of Enteral Nutrition Have a Greater Impact on Intestinal Microflora Than Surgical Resection Alone. ( Levesque, CL; Li, J; Lim, D; St Pierre, B; Turner, J; Wales, P; Wizzard, P, 2017) |
| "The prophylactic effect of in-feed medication of conventional pigs with sulphadimethoxine (SDM), sulphamethoxazole (SMX), and trimethoprim (TMP) was tested by using an Actinobacillus pleuropneumoniae infection model." | 3.70 | Prevention of pleuropneumonia in pigs by in-feed medication with sulphadimethoxine and sulphamethoxazole in combination with trimethoprim. ( Kuiper, HA; Mengelers, MJ; Pijpers, A; van Miert, AS; Verheijden, JH, 2000) |
| "Trimethoprim-sulfadiazine and gentamicin sulfate decreased early mortality in an established model of fibrinous peritonitis in the rat." | 3.67 | Efficacies of trimethoprim-sulfadiazine and gentamicin sulfate in the treatment of fibrinous peritonitis in rats. ( Benson, CE; Emms, SG, 1987) |
| "Co-trimazine, a new combination of trimethoprim and sulphadiazine intended for treatment of urinary tract infections, was tested and compared to co-trimoxazole in an experimental model of acute, obstructive pyelonephritis in the rat." | 3.66 | Efficacy of two trimethoprim-sulphonamide combinations in experimental pyelonephritis in the rat. ( Ritzerfeld, W, 1979) |
| "The results of the treatment of chronic bacterial prostatitis are disappointing." | 2.36 | Chronic bacterial prostatitis: theoretical and experimental considerations. ( Iversen, P; Jensen, KM; Madsen, PO, 1983) |
| "Conventional symptomatic treatment for Parkinson's disease (PD) with long-term L-3,4-dihydroxyphenylalanine (DOPA) is complicated with development of drug-induced side effects." | 1.42 | Controlled Striatal DOPA Production From a Gene Delivery System in a Rodent Model of Parkinson's Disease. ( Broom, L; Cederfjäll, E; Kirik, D, 2015) |
| "Trimethoprim/sulfadiazine treatment resulted in a marked reduction of viable bacteria in the tissue chamber but did not eliminate the infection, resulting in abscessation from day 19 onwards in all six ponies." | 1.33 | Clinical efficacy of prophylactic administration of trimethoprim/sulfadiazine in a Streptococcus equi subsp. zooepidemicus infection model in ponies. ( Bosch, G; Ensink, JM; van Duijkeren, E, 2005) |
| " In the chronic cystogenic murine models, the combination TMP plus SMX administered from day 5 for 15 days or from day 28 for 288 days, gave protection and even apparent toxoplasmal eradication ('cure') at the highest dosing (60/300 mg/kg per day)." | 1.30 | Evaluation of trimethoprim and sulphamethoxazole as monotherapy or in combination in the management of toxoplasmosis in murine models. ( Dumas, JL; Pechère, JC; Pizzolato, G, 1999) |
| "Trimethoprim K values were also not affected by model testing sequence (p = 0/760), but were by model type (p = 0." | 1.29 | Comparison of two otitis media models for the study of middle ear antimicrobial pharmacokinetics. ( Canafax, DM; Erdmann, GR; Giebink, GS; Le, CT; Lovdahl, MJ; Russlie, H, 1994) |
| " Ro 11-8958, TMP, and diaveridine used at a dosage of 20 mg/kg/day with SMX were only slightly more effective than SMX used alone." | 1.29 | Synergistic combinations of Ro 11-8958 and other dihydrofolate reductase inhibitors with sulfamethoxazole and dapsone for therapy of experimental pneumocystosis. ( Foy, J; Steele, P; Walzer, PD; White, M, 1993) |
| " The pharmacokinetic parameters of the sulfonamides as well as their main metabolites (acetyl sulfonamides) were not significantly different in healthy and febrile pigs." | 1.29 | Pharmacokinetics of sulfadimethoxine and sulfamethoxazole in combination with trimethoprim after intravenous administration to healthy and pneumonic pigs. ( Kuiper, HA; Mengelers, MJ; Pijpers, A; Van Gogh, ER; Van Miert, AS; Verheijden, JH, 1995) |
| "A rabbit serosal scarification model was utilized to compare the ability of four drugs, previously administered peri-operatively to horses undergoing exploratory celiotomy, to prevent the development of postoperative intestinal adhesions." | 1.29 | Utilization of the serosal scarification model of postoperative intestinal adhesion formation to investigate potential adhesion-preventing substances in the rabbit. ( Barker, IK; Conlon, PD; Hurtig, MB; Livesey, MA; Singer, ER, 1996) |
| "Pneumocystis carinii pneumonia is a major cause of death in AIDS patients in the United States." | 1.28 | Treatment of Pneumocystis carinii pneumonia with 1,3-beta-glucan synthesis inhibitors. ( Fromtling, RA; Nollstadt, KH; Pittarelli, LA; Romancheck, MA; Schmatz, DM; Schwartz, RE; Turner, MJ; Vanmiddlesworth, FL; Wilson, KE, 1990) |
| "Antimicrobial treatment of otitis media, especially drug dosing considerations, is largely empiric, with few reported pharmacologic studies of drug distribution into the middle ear." | 1.28 | Experimental animal models for studying antimicrobial pharmacokinetics in otitis media. ( Canafax, DM; Erdmann, GR; Giebink, GS; Juhn, SK; Le, CT; Nonomura, N, 1989) |
| "The purpose of this study was to identify new drugs for the prevention and treatment of Pneumocystis carinii pneumonitis (PCP) induced in rats by continuous daily dosage with dexamethasone." | 1.27 | Efficacy of diaminodiphenylsulfone and other drugs in murine Pneumocystis carinii pneumonitis. ( Hughes, WT; Smith, BL, 1984) |
| "Suramin and dapsone were weakly active." | 1.27 | Efficacy of DL-alpha-difluoromethylornithine in a rat model of Pneumocystis carinii pneumonia. ( Clarkson, AB; Rosenberg, C; Williams, DE, 1988) |
| " Administration of the TMP-SDZ combination at a dosage of 30 mg/kg once daily was not effective in maintaining TMP or SDZ concentrations above the MIC of TMP-SDZ for the S aureus (0." | 1.27 | Serum and synovial fluid steady-state concentrations of trimethoprim and sulfadiazine in horses with experimentally induced infectious arthritis. ( Bertone, AL; Jones, RL; McIlwraith, CW, 1988) |
| "Pentamidine was administered three times weekly via a Bird micronebulizer." | 1.27 | Pentamidine aerosol in prophylaxis and treatment of murine Pneumocystis carinii pneumonia. ( Brun-Pascaud, M; Farinotti, R; Girard, PM; Kernbaum, S; Tamisier, L, 1987) |
| "Norfloxacin was substantially more effective than trimethoprim-sulphamethoxazole in reducing the number of colony forming units from kidney homogenates when the test animals were diabetic." | 1.27 | Norfloxacin versus trimethoprim-sulphamethoxazole: efficacy in a model of ascending urinary tract infection in normal and streptozotocin-induced diabetic mice. ( Abruzzo, GK; Fromtling, RA; Gadebusch, HH; Gilfillan, EC; Pelak, BA, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 28 (51.85) | 18.7374 |
| 1990's | 9 (16.67) | 18.2507 |
| 2000's | 3 (5.56) | 29.6817 |
| 2010's | 12 (22.22) | 24.3611 |
| 2020's | 2 (3.70) | 2.80 |
| Authors | Studies |
|---|---|
| Gangjee, A | 1 |
| Shi, J | 1 |
| Queener, SF | 2 |
| Barrows, LR | 1 |
| Kisliuk, RL | 1 |
| Avdeef, A | 1 |
| Tam, KY | 1 |
| Solinski, HJ | 1 |
| Dranchak, P | 1 |
| Oliphant, E | 1 |
| Gu, X | 1 |
| Earnest, TW | 1 |
| Braisted, J | 1 |
| Inglese, J | 1 |
| Hoon, MA | 1 |
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Pearson, CS | 1 |
| Solano, AG | 1 |
| Tilve, SM | 1 |
| Mencio, CP | 1 |
| Martin, KR | 1 |
| Geller, HM | 1 |
| Sellmyer, MA | 1 |
| Lee, I | 1 |
| Hou, C | 1 |
| Weng, CC | 1 |
| Li, S | 1 |
| Lieberman, BP | 1 |
| Zeng, C | 1 |
| Mankoff, DA | 1 |
| Mach, RH | 1 |
| Jee, J | 1 |
| Mourya, R | 1 |
| Shivakumar, P | 1 |
| Fei, L | 1 |
| Wagner, M | 1 |
| Bezerra, JA | 1 |
| Slingerland, BCGC | 1 |
| Keehnen, M | 1 |
| Ouwerling, B | 1 |
| Tavakol, M | 1 |
| Snijders, SV | 1 |
| Verbrugh, HA | 1 |
| Vos, MC | 1 |
| Remarque, EJ | 1 |
| Langermans, JAM | 1 |
| van Wamel, WJB | 1 |
| Huang, L | 1 |
| Ozawa, M | 1 |
| Miyamoto-Sato, E | 1 |
| Chojnacki, M | 1 |
| Philbrick, A | 1 |
| Wucher, B | 1 |
| Reed, JN | 1 |
| Tomaras, A | 1 |
| Dunman, PM | 1 |
| Wozniak, RAF | 1 |
| Bayston, R | 1 |
| Ashraf, W | 1 |
| Pelegrin, I | 1 |
| Fowkes, K | 1 |
| Bienemann, AS | 1 |
| Singleton, WGB | 1 |
| Scott, IS | 1 |
| Quintino, L | 1 |
| Manfré, G | 1 |
| Wettergren, EE | 1 |
| Namislo, A | 1 |
| Isaksson, C | 1 |
| Lundberg, C | 1 |
| Hobbs, CV | 1 |
| Neal, J | 1 |
| Conteh, S | 1 |
| Donnelly, L | 1 |
| Chen, J | 1 |
| Marsh, K | 1 |
| Lambert, L | 1 |
| Orr-Gonzalez, S | 1 |
| Hinderer, J | 1 |
| Healy, S | 1 |
| Borkowsky, W | 1 |
| Penzak, SR | 1 |
| Chakravarty, S | 1 |
| Hoffman, SL | 1 |
| Duffy, PE | 1 |
| Cederfjäll, E | 1 |
| Broom, L | 1 |
| Kirik, D | 1 |
| Levesque, CL | 1 |
| Turner, J | 1 |
| Li, J | 1 |
| Wizzard, P | 1 |
| St Pierre, B | 1 |
| Lim, D | 1 |
| Wales, P | 1 |
| N'guessan, K | 1 |
| Dosso, M | 1 |
| Marchal, G | 1 |
| Chavarot, P | 1 |
| Romain, F | 1 |
| Pescher, P | 1 |
| Ensink, JM | 1 |
| Bosch, G | 1 |
| van Duijkeren, E | 1 |
| Hughes, WT | 2 |
| Smith, BL | 1 |
| Madsen, PO | 1 |
| Jensen, KM | 1 |
| Iversen, P | 1 |
| Rasková, H | 1 |
| Iqbal, MP | 1 |
| Niazi, SK | 1 |
| Ashfaq, MK | 1 |
| Mahboobali, N | 1 |
| Killmar, JT | 1 |
| Oz, HS | 1 |
| Canafax, DM | 2 |
| Russlie, H | 1 |
| Lovdahl, MJ | 1 |
| Erdmann, GR | 2 |
| Le, CT | 2 |
| Giebink, GS | 2 |
| Walzer, PD | 1 |
| Foy, J | 1 |
| Steele, P | 1 |
| White, M | 1 |
| Mengelers, MJ | 2 |
| Van Gogh, ER | 1 |
| Kuiper, HA | 2 |
| Pijpers, A | 2 |
| Verheijden, JH | 2 |
| Van Miert, AS | 2 |
| Singer, ER | 1 |
| Livesey, MA | 1 |
| Barker, IK | 1 |
| Hurtig, MB | 1 |
| Conlon, PD | 1 |
| Dumas, JL | 1 |
| Pizzolato, G | 1 |
| Pechère, JC | 1 |
| Dhondt, JL | 2 |
| Farriaux, JP | 2 |
| Dautrevaux, M | 1 |
| Biserte, G | 1 |
| Hamilton-Miller, JM | 1 |
| Arioli, V | 1 |
| Berti, M | 1 |
| Carniti, G | 1 |
| Rossi, E | 1 |
| Ritzerfeld, W | 2 |
| Davidson, DE | 1 |
| Johnsen, DO | 1 |
| Tanticharoenyos, P | 1 |
| Hickman, RL | 1 |
| Kinnamon, KE | 1 |
| Schmatz, DM | 1 |
| Romancheck, MA | 1 |
| Pittarelli, LA | 1 |
| Schwartz, RE | 1 |
| Fromtling, RA | 2 |
| Nollstadt, KH | 1 |
| Vanmiddlesworth, FL | 1 |
| Wilson, KE | 1 |
| Turner, MJ | 1 |
| Nonomura, N | 1 |
| Juhn, SK | 1 |
| Bartlett, MS | 1 |
| Durkin, MM | 1 |
| Jay, MA | 1 |
| Smith, JW | 1 |
| Pueschel, SM | 1 |
| Boylan, J | 1 |
| Ellenbogen, R | 1 |
| Clarkson, AB | 1 |
| Williams, DE | 1 |
| Rosenberg, C | 1 |
| Bertone, AL | 1 |
| Jones, RL | 1 |
| McIlwraith, CW | 1 |
| Muhvich, KH | 1 |
| Myers, RA | 1 |
| Marzella, L | 1 |
| Domer, JE | 1 |
| Hector, RF | 1 |
| Girard, PM | 1 |
| Brun-Pascaud, M | 1 |
| Farinotti, R | 1 |
| Tamisier, L | 1 |
| Kernbaum, S | 1 |
| Gelber, RH | 1 |
| Emms, SG | 1 |
| Benson, CE | 1 |
| Abruzzo, GK | 1 |
| Gilfillan, EC | 1 |
| Pelak, BA | 1 |
| Gadebusch, HH | 1 |
| Kawaler, B | 1 |
| Hof, H | 1 |
| Lindner, A | 1 |
| Rudas, B | 1 |
| Selzer, H | 1 |
| Vischer, WA | 1 |
| Prát, V | 1 |
| Hatala, M | 1 |
| Konícková, L | 1 |
| Van der Waaij, D | 1 |
| Cohen, BJ | 1 |
| Anver, MR | 1 |
| Philippon, A | 1 |
| Kazmierczak, A | 1 |
| Névot, P | 1 |
| Freerksen, E | 1 |
| Rosenfeld, M | 1 |
| Roy, AD | 1 |
| Cameron, HM | 1 |
2 reviews available for trimethoprim and Disease Models, Animal
| Article | Year |
|---|---|
Chronic bacterial prostatitis: theoretical and experimental considerations.
Topics: Animals; Antibody Formation; Antibody-Coated Bacteria Test, Urinary; Bacterial Infections; Chronic D | 1983 |
Antimicrobial agents acting against anaerobes.
Topics: Aminoglycosides; Anaerobiosis; Animals; Anti-Bacterial Agents; Bacteria; Chloramphenicol; Clindamyci | 1975 |
52 other studies available for trimethoprim and Disease Models, Animal
| Article | Year |
|---|---|
Synthesis of 5-methyl-5-deaza nonclassical antifolates as inhibitors of dihydrofolate reductases and as potential antipneumocystis, antitoxoplasma, and antitumor agents.
Topics: Animals; Antineoplastic Agents; Disease Models, Animal; Folic Acid Antagonists; Fungal Proteins; Hum | 1993 |
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
Topics: Animals; Disease Models, Animal; Dogs; Humans; Jejunal Diseases; Kidney Diseases; Models, Biological | 2010 |
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
Topics: Animals; Behavior, Animal; Cell-Free System; Dermatitis, Contact; Disease Models, Animal; Ganglia, S | 2019 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
Spatiotemporal distribution of chondroitin sulfate proteoglycans after optic nerve injury in rodents.
Topics: Aggrecans; Animals; Brevican; Chondroitin Sulfate Proteoglycans; Crush Injuries; Disease Models, Ani | 2020 |
Bacterial infection imaging with [
Topics: Animals; Anti-Bacterial Agents; Cell Line; Disease Models, Animal; Escherichia coli; Escherichia col | 2017 |
Cxcr2 signaling and the microbiome suppress inflammation, bile duct injury, and the phenotype of experimental biliary atresia.
Topics: Animals; Bile Ducts; Biliary Atresia; Disease Models, Animal; Female; Gene Expression Profiling; Inf | 2017 |
An experimental Staphylococcus aureus carriage and decolonization model in rhesus macaques (Macaca mulatta).
Topics: Administration, Intranasal; Animals; Anti-Bacterial Agents; Carrier State; Disease Models, Animal; D | 2018 |
Development of a novel conditional knockdown mouse based on YB-1 protein degradation.
Topics: Animals; Disease Models, Animal; Mice; Mice, Knockout; Mice, Transgenic; Protein Engineering; Proteo | 2018 |
Development of a Broad-Spectrum Antimicrobial Combination for the Treatment of Staphylococcus aureus and Pseudomonas aeruginosa Corneal Infections.
Topics: Animals; Anti-Bacterial Agents; Cornea; Disease Models, Animal; Drug Resistance, Multiple, Bacterial | 2019 |
An external ventricular drainage catheter impregnated with rifampicin, trimethoprim and triclosan, with extended activity against MDR Gram-negative bacteria: an in vitro and in vivo study.
Topics: Animals; Anti-Bacterial Agents; Bacterial Infections; Catheter-Related Infections; Catheterization; | 2019 |
Functional neuroprotection and efficient regulation of GDNF using destabilizing domains in a rodent model of Parkinson's disease.
Topics: Animals; Cell Line, Tumor; Disease Models, Animal; Escherichia coli; Escherichia coli Proteins; Fema | 2013 |
HIV treatments reduce malaria liver stage burden in a non-human primate model of malaria infection at clinically relevant concentrations in vivo.
Topics: Animals; Antimalarials; Disease Models, Animal; Drug Combinations; HIV Protease Inhibitors; Liver; L | 2014 |
Controlled Striatal DOPA Production From a Gene Delivery System in a Rodent Model of Parkinson's Disease.
Topics: Animals; Behavior, Animal; Biomarkers; Cell Line; Corpus Striatum; Dependovirus; Dihydroxyphenylalan | 2015 |
In a Neonatal Piglet Model of Intestinal Failure, Administration of Antibiotics and Lack of Enteral Nutrition Have a Greater Impact on Intestinal Microflora Than Surgical Resection Alone.
Topics: Ampicillin; Animals; Animals, Newborn; Anti-Bacterial Agents; Disease Models, Animal; DNA, Bacterial | 2017 |
[Preliminary study on isoniazid-epiroprim combination in a tuberculosis murine model].
Topics: Animals; Antitubercular Agents; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Therapy, | 2002 |
Clinical efficacy of prophylactic administration of trimethoprim/sulfadiazine in a Streptococcus equi subsp. zooepidemicus infection model in ponies.
Topics: Administration, Oral; Animals; Anti-Bacterial Agents; Antibiotic Prophylaxis; Disease Models, Animal | 2005 |
Efficacy of diaminodiphenylsulfone and other drugs in murine Pneumocystis carinii pneumonitis.
Topics: Animals; Dapsone; Disease Models, Animal; Drug Combinations; Male; Pneumonia, Pneumocystis; Rats; Ra | 1984 |
[Transfer of data to man and pathological models].
Topics: Animals; Aspirin; Cattle; Diarrhea; Disease Models, Animal; Humans; Kinetics; Sulfamethazine; Trimet | 1982 |
Pharmacokinetics of aditoprim in normal and febrile sheep.
Topics: Animals; Bacterial Infections; Disease Models, Animal; Enzyme Inhibitors; Fever; Rectum; Sheep; Time | 1995 |
Relative potency of 10 drugs with anti-Pneumocystis carinii activity in an animal model.
Topics: Animals; Anti-Infective Agents; Atovaquone; Azithromycin; Clarithromycin; Clindamycin; Clinical Tria | 1994 |
Comparison of two otitis media models for the study of middle ear antimicrobial pharmacokinetics.
Topics: Amoxicillin; Animals; Anti-Bacterial Agents; Chinchilla; Diffusion; Disease Models, Animal; Ear, Mid | 1994 |
Synergistic combinations of Ro 11-8958 and other dihydrofolate reductase inhibitors with sulfamethoxazole and dapsone for therapy of experimental pneumocystosis.
Topics: AIDS-Related Opportunistic Infections; Animals; Dapsone; Disease Models, Animal; Dose-Response Relat | 1993 |
Pharmacokinetics of sulfadimethoxine and sulfamethoxazole in combination with trimethoprim after intravenous administration to healthy and pneumonic pigs.
Topics: Actinobacillus Infections; Actinobacillus pleuropneumoniae; Animals; Anti-Bacterial Agents; Bacteria | 1995 |
Utilization of the serosal scarification model of postoperative intestinal adhesion formation to investigate potential adhesion-preventing substances in the rabbit.
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Carboxymeth | 1996 |
Evaluation of trimethoprim and sulphamethoxazole as monotherapy or in combination in the management of toxoplasmosis in murine models.
Topics: Animals; Chronic Disease; Disease Models, Animal; Drug Evaluation; Mice; Sulfamethoxazole; Toxoplasm | 1999 |
Prevention of pleuropneumonia in pigs by in-feed medication with sulphadimethoxine and sulphamethoxazole in combination with trimethoprim.
Topics: Actinobacillus Infections; Actinobacillus pleuropneumoniae; Animal Feed; Animals; Anti-Bacterial Age | 2000 |
Study of blood aminoacids in experimental hyperphenylalaninemia.
Topics: Amino Acids; Animals; Disease Models, Animal; Fenclonine; Humans; Male; Phenylalanine; Phenylketonur | 1977 |
A new experimental model of hyperphenylalaninemia in rat. Effect of p-chlorophenylalanine and cotrimoxazole.
Topics: Animals; Disease Models, Animal; Drug Combinations; Fenclonine; Humans; Kidney; Liver; Male; Phenyla | 1977 |
Interaction between rifampicin and trimethoprim in vitro and in experimental infections.
Topics: Animals; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Enterobacteriaceae; Ente | 1977 |
Efficacy of two trimethoprim-sulphonamide combinations in experimental pyelonephritis in the rat.
Topics: Animals; Disease Models, Animal; Drug Administration Schedule; Drug Combinations; Escherichia coli I | 1979 |
Evaluating new antimalarial drugs against trophozoite induced Plasmodium cynomolgi malaria in rhesus monkeys.
Topics: Amodiaquine; Animals; Antimalarials; Dapsone; Disease Models, Animal; Dose-Response Relationship, Dr | 1976 |
Treatment of Pneumocystis carinii pneumonia with 1,3-beta-glucan synthesis inhibitors.
Topics: Animals; Anti-Bacterial Agents; Antifungal Agents; Candida albicans; Disease Models, Animal; Echinoc | 1990 |
Experimental animal models for studying antimicrobial pharmacokinetics in otitis media.
Topics: Amoxicillin; Animals; Anti-Infective Agents; Chinchilla; Disease Models, Animal; Ear, Middle; Eustac | 1989 |
Sources of rats free of latent Pneumocystis carinii.
Topics: Animals; Disease Models, Animal; Drug Combinations; Female; Immunosuppression Therapy; Pneumonia, Pn | 1987 |
Studies on experimentally induced hyperphenylalaninemia.
Topics: Animals; Disease Models, Animal; Drug Combinations; Female; Fenclonine; Phenylalanine; Phenylalanine | 1988 |
Efficacy of DL-alpha-difluoromethylornithine in a rat model of Pneumocystis carinii pneumonia.
Topics: Amphotericin B; Animals; Antiprotozoal Agents; Dapsone; Diminazene; Disease Models, Animal; Drug Com | 1988 |
Serum and synovial fluid steady-state concentrations of trimethoprim and sulfadiazine in horses with experimentally induced infectious arthritis.
Topics: Administration, Oral; Animals; Anti-Bacterial Agents; Arthritis, Infectious; Disease Models, Animal; | 1988 |
Effect of hyperbaric oxygenation, combined with antimicrobial agents and surgery, in a rat model of intraabdominal infection.
Topics: Abdomen; Abscess; Animals; Anti-Bacterial Agents; Bacteroides fragilis; Bacteroides Infections; Dise | 1988 |
Enhanced immune responses in mice treated with penicillin-tetracycline or trimethoprim-sulfamethoxazole when colonized intragastrically with Candida albicans.
Topics: Animals; Antibodies, Fungal; Candida albicans; Candidiasis; Disease Models, Animal; Drug Combination | 1987 |
Pentamidine aerosol in prophylaxis and treatment of murine Pneumocystis carinii pneumonia.
Topics: Aerosols; Amidines; Animals; Anti-Infective Agents; Chromatography, High Pressure Liquid; Disease Mo | 1987 |
The use of rodent models in assessing antimicrobial activity against Mycobacterium leprae.
Topics: Animals; Anti-Bacterial Agents; Disease Models, Animal; Drug Evaluation, Preclinical; Mice; Microbia | 1986 |
Efficacies of trimethoprim-sulfadiazine and gentamicin sulfate in the treatment of fibrinous peritonitis in rats.
Topics: Animals; Disease Models, Animal; Drug Combinations; Gentamicins; Male; Peritonitis; Rats; Rats, Inbr | 1987 |
Norfloxacin versus trimethoprim-sulphamethoxazole: efficacy in a model of ascending urinary tract infection in normal and streptozotocin-induced diabetic mice.
Topics: Animals; Anti-Infective Agents; Diabetes Mellitus, Experimental; Disease Models, Animal; Drug Combin | 1985 |
Murine model for therapy of listeriosis in the compromised host. IV. Cotrimoxazole.
Topics: Ampicillin; Animals; Anti-Infective Agents, Urinary; Disease Models, Animal; Drug Combinations; Fema | 1985 |
[Comparative studies on the effect of antibacterial substances on inflammation and wound healing in rats].
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Carrageenan; Dactin | 1972 |
[Comparative study on the effect of some clinically used sulfanilamide derivatives against toxoplasmosis in the mouse].
Topics: Aminobenzoates; Animals; Dapsone; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Syn | 1973 |
[Models of urinary infection].
Topics: Animals; Bacterial Infections; Bacteriuria; Carbenicillin; Disease Models, Animal; Drug Therapy, Com | 1974 |
Mitigation of experimental inflammatory bowel disease in guinea pigs by selective elimination of the aerobic gram-negative intestinal microflora.
Topics: Animals; Bacteria; Body Weight; Carrageenan; Cecum; Colitis, Ulcerative; Colon; Disease Models, Anim | 1974 |
[Treatment of brucellosis associated with corynebacterium parvum infection in mice with antibiotics (tetracycline, ampicillin, trimethoprim-sulfamethoxazole)].
Topics: Ampicillin; Animals; Brucellosis; Cell Count; Complement Fixation Tests; Corynebacterium Infections; | 1972 |
A new analogous model for the detection and evaluation of chemotherapeutic products effective in leprosy.
Topics: Aniline Compounds; Animals; Dapsone; Disease Models, Animal; Drug Combinations; Ethionamide; Humans; | 1972 |
Rhinophycomycosis entomophthorae occurring in a chimpanzee in the wild in East Africa.
Topics: Africa, Eastern; Animals; Disease Models, Animal; Female; Fungi; Mycoses; Nose; Nose Diseases; Pan t | 1972 |